|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006118,
umls-concept:C0013216,
umls-concept:C0025723,
umls-concept:C0070167,
umls-concept:C0086860,
umls-concept:C0205618,
umls-concept:C0220901,
umls-concept:C0681890,
umls-concept:C0684224,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1334505,
umls-concept:C1335110,
umls-concept:C1516985,
umls-concept:C1522673,
umls-concept:C2603343
|
|
pubmed:issue |
35
|
|
pubmed:dateCreated |
2009-12-9
|
|
pubmed:abstractText |
O6-methylguanine-methyltransferase (MGMT) promoter methylation has been shown to predict survival of patients with glioblastomas if temozolomide is added to radiotherapy (RT). It is unknown if MGMT promoter methylation is also predictive to outcome to RT followed by adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in patients with anaplastic oligodendroglial tumors (AOT).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BrandesAlba AAA,
pubmed-author:DinjensWinand N MWN,
pubmed-author:DubbinkHendrikus JHJ,
pubmed-author:FrenayMarcM,
pubmed-author:GorliaThierryT,
pubmed-author:HegiMonikaM,
pubmed-author:IbdaihAhmedA,
pubmed-author:JeukenJudith W MJW,
pubmed-author:KrosJohan MJM,
pubmed-author:LacombeDenisD,
pubmed-author:SansonMarcM,
pubmed-author:TaphoornMartin J BMJ,
pubmed-author:van den BentMartin JMJ,
pubmed-author:van der Lee-HaarlooCathleen RCR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5881-6
|
|
pubmed:dateRevised |
2010-12-14
|
|
pubmed:meshHeading |
pubmed-meshheading:19901104-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19901104-Astrocytoma,
pubmed-meshheading:19901104-Brain Neoplasms,
pubmed-meshheading:19901104-Chemotherapy, Adjuvant,
pubmed-meshheading:19901104-Chromosome Deletion,
pubmed-meshheading:19901104-Chromosomes, Human, Pair 1,
pubmed-meshheading:19901104-Chromosomes, Human, Pair 19,
pubmed-meshheading:19901104-CpG Islands,
pubmed-meshheading:19901104-DNA Methylation,
pubmed-meshheading:19901104-DNA Modification Methylases,
pubmed-meshheading:19901104-DNA Repair Enzymes,
pubmed-meshheading:19901104-Disease-Free Survival,
pubmed-meshheading:19901104-Europe,
pubmed-meshheading:19901104-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19901104-Humans,
pubmed-meshheading:19901104-Kaplan-Meier Estimate,
pubmed-meshheading:19901104-Lomustine,
pubmed-meshheading:19901104-Middle Aged,
pubmed-meshheading:19901104-Oligodendroglioma,
pubmed-meshheading:19901104-Polymerase Chain Reaction,
pubmed-meshheading:19901104-Procarbazine,
pubmed-meshheading:19901104-Promoter Regions, Genetic,
pubmed-meshheading:19901104-Proportional Hazards Models,
pubmed-meshheading:19901104-Risk Assessment,
pubmed-meshheading:19901104-Risk Factors,
pubmed-meshheading:19901104-Time Factors,
pubmed-meshheading:19901104-Treatment Outcome,
pubmed-meshheading:19901104-Tumor Suppressor Proteins,
pubmed-meshheading:19901104-Vincristine
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
|
|
pubmed:affiliation |
Department of Neuro-Oncology and Pathology, Daniel den Hoed Cancer Center and Erasmus University Medical Center, Rotterdam, the Netherlands. m.vandenbent@erasmusmc.nl
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
